Astrizi Therapeutics is an Austrian biotechnology company developing innovative oral small molecule drugs to treat obesity and neurodegenerative diseases by restoring mitochondrial function and cellular homeostasis. The company's platform targets mitochondrial dysfunction to improve cellular energy metabolism, promote the removal of toxic proteins, and reverse metabolic aging. Its lead candidate, AS 005, is an oral therapy designed to repair mitochondrial damage and reduce inflammation in obesity and other cardiometabolic diseases. The team combines expertise in drug development, metabolism, and neurology to translate these biological approaches into practical, once-daily oral therapies for chronic diseases with high disease burden.
Gaalerstraße 2a
8720 Knittelfeld